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NUTRITIONAL SUPPORT: A SURVEY OF PEDIATRIC BLOOD AND MAR-
ROW TRANSPLANT CONSORTIUM INSTITUTIONS
Olson, E.A.1, Fisher, V.L.2, Barnes, Y.J.3, Skeens, M.A.4, Niess, D.5
1Children’s Healthcare of Atlanta, AFLAC Cancer Center & Blood
Disorder Service, Emory University Department of Pediatrics, Atlanta,
GA; 2Rainbow Babies and Children’s Hospital, Ireland Cancer Center,
Cleveland, OH; 3St Louis Children’s Hospital, St. Louis, MO; 4Colum-
bus Children’s Hospital, Columbus, OH; 5Children’s Hospitals of Min-
nesota, Minneapolis, MN.
Purpose: This survey was designed to identify the nutritional
practices used for the pediatric blood and marrow transplant
(BMT) patient by institutions within the Pediatric Blood and
Marrow Transplant Consortium (PBMTC). A secondary aim is to
develop a standard of care for nutritional support for the pediatric
BMT patient.
Methods: A survey was distributed to member institutions at the
semi-annual PBMTC meeting. The survey was designed to collect
information about institutional demographics, transplant speciﬁc
nutritional practices, and supportive care.
Results: Seventy-eight percent of the surveys were returned.
Both allogeneic and autologous transplant procedures were per-
formed at 94% of the institutions. The majority of institutions used
total body irradiation (TBI) in at least 25% of the conditioning
regimens. There were no nutritional practice differences between
myeloablative and non myeloablative transplants. Seventy-ﬁve per-
cent of centers reported using mucositis prophylaxis, the majority
utilized glutamine (40%) and/or trophic feeds (28%). At some
point during the transplant course, ninety-four percent of institu-
tions still reported using hyperalimentation. Parental nutrition was
not used at two institutions. Two thirds of the centers utilized
continuous nasogastric (NG) feeds. Ninty percent of institutions
employed oral supplementation in patients with chronic graft ver-
sus host disease, while approximately half of the institutions also
used enteral feeding. Various methods were used to control nausea,
vomiting, diarrhea, and gastric paresis. Education was provided by
inservice at 47% of the institutions. At time of discharge, multiple
nutritional supplements were prescribed.
Conclusion: Based on the submitted surveys, the PBMTC in-
stitutions employ various nutritional support practices. These ﬁnd-
ings suggest a need to develop a nutritional support standard of
care for the pediatric BMT patient. Further exploration of prac-
tices and outcomes is needed to expand evidence based nutritional
practices in the pediatric BMT patient.
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POST TRANSPLANT AUTOIMMUNE HEMOLYTIC ANEMIA AND OTHER
CYTOPENIAS ARE INCREASED IN YOUNG BABIES UNDERGOING UNRE-
LATED DONOR UMBILICAL CORD BLOOD TRANSPLANTATION
Page, K.M.1, Wood, S.1, Prasad, V.1, Szabolcs, P.1, Kurtzberg, J.1
1Duke University Medical Center, Durham, NC.
Unrelated donor umbilical cord blood transplantation (UCBT)
has shown great promise in the treatment of young babies with
early infantile, lysosomal storage diseases, hemoglobinopathies and
congenital bone marrow failure disorders. When a family history
of the disorder is present, subsequent affected babies can be diag-
nosed prenatally or at birth and transplanted in the ﬁrst 1-2 months
of life. Over the past 9 years, we have treated 16 neonates with
Krabbe disease (n9) metachromatic leukodystrophy (n1), Tay
Sachs disease (n1), Hurler syndrome (n2), Hunter syndrome
(n2) and beta thalassemia major (n1) with UCBT after myeloa-
blative conditioning therapy with Busulfan, Cyclophosphamide
and ATG. All babies received cyclosporine and methylprednisone
(n11) or cyclosporine  cellcept (n5) for prophylaxis against
GvHD which was continued at full dose for 6-9 months and then
weaned. All babies recieved high nucleated cell doses
(1010e7cells/kg) from their single cord blood unit. All but one
baby with Hunter syndrome maintained full donor chimerism.
Three patients died post transplant, 1 neonate with Krabbe of
persistant pulmonary hypertension in the ﬁrst 2 weeks post trans-
plant, 1 with Hunters who was a mixed chimera and died of
sequelae of chronic GvHD at 2 years of age and 1 with Tay Sachs
of sudden, unknown causes at 5 years of age. 57% of patients (8/14)
developed autoimmune hemolytic anemia alone or with thrombo-
cytopenia and neutropenia within the ﬁrst year post transplant in
the absence of signs of acute or chronic GvHD. All patients
responded to treatment with methylprednisolone, imuran /- rit-
uxan. Rapid withdrawal of cyclosporine was successful in all but 2
patients who broke through with evidence of chronic skin GvHD
controlled with FK-506. The high incidence of autoimmune dis-
ease post UCBT is unique to this population of very young babies.
Older children have been estimated to have a 4% chance of devel-
oping AHA. We hypothesize that pre and post transplant immu-
nosuppression interferes with the normal development of the im-
mune system in the ﬁrst year of life creating immune dysregulation
and graft directed cell destruction. After lytic agents to stabilize
disease, removal of chronic immunosuppressive therapy facilitates
resolution of the problem. Alternative strategies to prevent GvHD
should be developed for this unique patient population.
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OUTCOMES OF MATCHED RELATED DONOR BONE MARROW TRANS-
PLANTATION IN PEDIATRIC PATIENTS WITH MYELODYSPLASTIC SYN-
DROME
Parikh, S.H.1, Martin, P.L.1, Prasad, V.K.1, Szabolcs, P.1,
Driscoll, T.A.1, Kurtzberg, J.1 1Duke University Medical Center,
Durham, NC.
Myelodysplastic syndromes (MDS) in children are associated
with signiﬁcant morbidity and risk of leukemic transformation.
Allogeneic hematopoietic stem cell transplantation is the only
curative therapy. The ideal allogeneic donor is an HLA-identical
sibling or relative or Matched Related Donor (MRD). From 1990
to 2005, a total of 12 pediatric or young adult patients with MDS
received bone marrow transplant from an HLA matched sibling at
our institution. M:F ratio of the study group was 1.4; One patient
belonged to ethnic minorities (8%); the median age at transplant
was 13.4 years (range 1.1-20.6) and median weight was 54.7 kg
(range 10.8-78). Three patients had therapy-related MDS (2 ALL,
1 NHL). MDS stage was RA/RC in 2 pts, RARS in 1 pt, RAEB in
5 pts, RAEB-T in 2 pts, and AML in 2 pts. Monosomy 7 was
present in 3 (25%) pts. Median time from diagnosis to transplant
was 3 months (range 1.27-56.83). Preparative regimen was non-
TBI based in 10 (83%) pts. TBI was used for the only 2 (17%) pts
with AML. Eleven (92%) patients received melphalan. Cyclospor-
ine was used for GVHD prophylaxis with methotrexate in 10 pts
and Solu-medrol in 2 pts. The grafts contained a median of 2.1 
10e8 (range 0.7-8.46) nucleated cells/kg infused. Median time to
neutrophil recovery (ANC  500) was 15 days (range 10-33), and
that to platelet recovery (50K untransfused) was 44 days (range
29-150). Acute GVHD, grade 1-2, was seen in 7 (58%) patients;
none of the patients had grade 3-4 acute GVHD. Chronic GVHD
was seen in 2 (16.6%) patients, 1 limited to skin, and 1 extensive
involving skin and gut. The only patient with RARS died from
lactic acidosis. One patient, who had undergone a prior transplant
for ALL, acquired monosomy 7 clone 40 months later. She under-
went BMT from the same donor, relapsed again after 22 months,
underwent a third successful transplant from the same donor with
non-myeloablative conditioning and peripheral blood stem cells.
She is disease free 6 years from the last transplant. Thus, 11
(91.6%) of the 12 patients are surviving long term and disease free
with a median follow-up of 6.81 years (range 1.02-16.01). Bone
marrow transplant from matched sibling donor with non-TBI
based, melphalan containing regimen is very effective in curing
MDS affecting children and young adults.
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OUTCOMES OF UNRELATED UMBILICAL CORD BLOOD TRANSPLANTA-
TION IN PEDIATRIC PATIENTS WITH MYELODYSPLASTIC SYNDROME
Parikh, S.H.1, Mendizabal, A.2, Martin, P.L.1, Szabolcs, P.1,
Prasad, V.K.1, Driscoll, T.A.1, Kurtzberg, J.1 1Duke University Med-
ical Center, Durham, NC; 2Emmes Corporation, Rockville, MD.
Myelodysplastic syndromes (MDS) in children are associated
with signiﬁcant morbidity and risk of leukemic transformation.
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Allogeneic hematopoietic stem cell transplantation is the only
curative therapy. Many patients do not have a suitable donor.
Between 1995 – 2006, 25 pediatric patients lacking matched
living stem cell donors were transplanted with unrelated umbil-
ical cord blood (UCB). M:F ratio of the study group was 1.8;
Eight (32%) patients belonged to ethnic minorities; the median
age was 9.77 years (range 1.11-19.73) and median weight was
32.8 kg (range 8.3-62.6). Five patients had therapy-related MDS
(3 ALL, 1 NHL, 1 Neuroblastoma). MDS stage was RA/RC 10
pts, RAEB 7 pts, RAEB-T 3pts, and AML 5 pts. Monosomy 7
was present in 17 (68%) pts. Median time from diagnosis to
transplant was 7.17 months (range 2-61). Preparative regimen
was TBI based in 17 pts (68%). Cyclosporine was used for
GVHD prophylaxis with Solu-medrol in 24 pts and CellCept in
1 pt. Grafts were matched at HLA Class I (A and B) at low
resolution and HLA Class II (DRB1) at the allelic level. 6 pts
were 5/6, 18 pts were 4/6, and 1 pt was 3/6 HLA matched. The
grafts contained a median of 4.39  10e7 (range 1.68-29.16)
nucleated cells/kg pre-cryopreservation and 3.58  10e7/kg
(range 1.01-21.25) infused. The median CD 34 cell dose
infused was 1.5  10e5/kg (range 0.17-28.46). Cumulative in-
cidence of neutrophil engraftment (ANC  500/ L) at day 100,
platelet engraftment (50K untransfused) at day 180, acute
GVHD grades 2-4 at day 100, chronic GVHD, relapse and non
relapse mortality at 1 yr were 72%, 56%, 20%, 32%, 8% and
36.5% respectively. 5 yr probabilities of OS and EFS were 46%
and 41%. Thirteen patients died, 5 of infectious complications
(1 toxoplasmosis, 1 aspergillosis, 2 EBV including 1 LPD, 1
adenovirus), 4 of relapse, 1 of graft failure, and 3 of multi system
organ failure. EFS of pts  10 yrs of age (p  0.05) , weighing
 33kg (p  0.03), and those with monosomy 7 (p  0.05) was
superior. These results, especially in younger patients with
Monosomy 7 and early stage MDS are equivalent to matched
allogeneic bone marrow transplant data. We conclude that un-
related UCB donors should be actively considered for pediatric
patients with MDS who lack a living related or unrelated stem
cell donor to enable transplantation when the disease is in early
stage.
Event Free Survival by Covariates
N Events
1 yr estimate
%(95% CI)
3 yr estimate
(95% CI) p-value
KARYOTYPE 0.05
Monosomy 7
present
17 8 64.7 (42-87.4) 58.8 (35.4-82.2)
Monosomy 7
absent
8 6 37.5 (4-71) 18.8 (0-49.7)
RECIPIENT AGE 0.05
> 10 years 11 9 45.5 (16-74.9) 27.3 (1.0-53.6)
< 10 years 14 5 64.3 (39.2-89.4) 64.3 (39.2-89.4)
RECIPIENT WT. 0.03
> 33 kg 12 10 41.7 (13.8-69.6) 25 (0.5-49.5)
< 33 kg 13 4 69.2 (44.1-94.3) 69.2 (44.1-94.3)
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MYELOABLATIVE HSCT FOR CHILDREN AND ADOLESCENTS WITH LYM-
PHOMA REFRACTORY TO PRIMARY THERAPY: A SINGLE INSTITUTION
EXPERIENCE
Quinones, R.1, Peltz, A.1, Malcolm, J.1, Hild, E.1, Gore, L.1,
Foreman, N.1, Christensen, M.1, Croskell, M.1, Kissane, R.1, Giller, R.1
1University of Colorado and The Children’s Hospital, Denver, CO.
Primary therapy of high-risk lymphomas in children and ad-
olescents is very successful, however refractory lymphoma pre-
sents major challenges and optimal therapy remains uncertain.
Between 1994 and 2006, 22 pediatric patients with high-risk
lymphoma underwent myeloablative therapy and HSCT; 16
autologous and 7 allogeneic (5 sibling; 2 unrelated HSCT). The
overall EFS was 61% with a median follow up in survivors of
1243 days after HSCT. In 8 Hodgkin’s patients the overall EFS
was 54%; all patients had failed primary therapy, received au-
tologous PBPC and engrafted and one had a planned non-
myeloablative sibling allogeneic HSCT. Relapse occurred in 3
of 4 patients not in CR at 181, 248 and 812 days from HSCT.
In contrast, the 4 of the 5 relapse-free survivors (median follow
up of 833 days; range 305 to 2127) had attained a CR2. The 14
NHL patients’ diagnoses included 6 anaplastic large cell lym-
phomas, 2 peripheral T lymphomas and 6 lymphoblastic lym-
phomas (4 T and 2 B precursor phenotype). Allogeneic HSCT
were performed in 7 NHL patients (5 MS; 2 URD), while 8
patients received autologous PBPC (one autologous patient
relapsed at day 60, then received an allograft). All relapses
occurred before day 100 and 4/5 relapses were in patients who
either had CNS relapses and/or had residual disease at the time
of HSCT. The EFS for all NHL patients was 67% with a
median follow up in survivors of 1756 days (range 224 to 3606
days). In autologous HSCT recipients, the EFS was 50% (me-
dian follow up in survivors was 1071 days; range 224 to 2527),
while after allogeneic HSCT for NHL, the EFS was 83%
(median follow up in survivors was 2283 days; range 496 to
3606). There were no toxic deaths in any patient group. GVHD
occurred in 3/7 allogeneic HSCT patients and resolved with
therapy in all patients. Opportunistic infections typical for al-
logeneic HSCT (speciﬁcally aspergillus, CMV and RSV) oc-
curred more often in the lymphoma patients undergoing autol-
ogous PBPC HSCT compared to pediatric autologous HSCT in
patients with solid tumors. We conclude that myeloablative
HSCT offers signiﬁcant salvage potential in patients with lym-
phoma who have disease refractory to primary therapy. Those
patients who attain disease control prior to HSCT do very well.
We prefer to use TBI-based myeloablation and perform alloge-
neic HSCT in pediatric NHL patients to overcome potential
chemotherapy resistance, decrease the potential of re-infused
tumor and to potentially elicit a GVL effect.
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REDUCED INTENSITY CONDITIONING (RIC) AND HEMATOPOIETIC
STEM CELL TRANSPLANTATIATION (HSCT) USING PHOTOPHERESIS
(ECP), FLUDARABINE, AND TARGETED SINGLE DOSE BUSULFAN AS AN
OUTPATIENT PROCEDURE IN CHILDREN: PRELIMINARY RESULTS
Schneiderman, J.1, Duerst, R.1, Tse, W.1, Thormann, K.1, Kletzel, M.1,
Jacobsohn, D.A.1 1Northwestern University, Chicago, IL.
ECP is an immunomodulatory therapy for immune-mediated
disorders, including GVHD. We hypothesize that combining
ECP with RIC prior to and following HSCT will reduce inci-
dence of GVHD and 100-day transplant related mortality
(TRM) without affecting time to engraftment. Ten children
have been enrolled with a mean age of 14 years (10 – 17), with
CML (n2), severe aplastic anemia (SAA) (n4), ALL in CR2
(n1), peripheral T-cell lymphoma (n1), and relapsed
Hodgkin’s after autologous transplant (n2). Stem cell sources
included peripheral blood from matched related (n6), mis-
matched related (n1), and matched unrelated (n3) donors.
Conditioning included 2 weekly treatments of ECP (treat-
ment2 consecutive days) beginning two weeks prior to trans-
plant, ﬂudarabine 30mg/m2/d (days -6 to -2) and targeted dose
busulfan to reach a daily AUC of 4000 mol*min (days -5, -4);
GVHD prophylaxis was: MMF, CSA, and weekly ECP once
total chimerism reached 50% through day 100. Median fol-
low-up is 100 days (33 – 446). Full engraftment (95% total
donor chimerism) was achieved by a median of 29 days (12 – 81)
in 9/10 patients. Two required immune modulation for falling
chimerism; 1 responded to removal of immune suppression, 1
required donor lymphocyte infusion. Major complications were
infectious: central line infections (n5, with 1 episode of hypo-
tension), adenovirus antigenemia (n1), and CMV reactivation
(n5/5 at risk); they underwent pre-emptive treatment without
development of disease. There was 1 TRM: a patient with
heavily treated SAA died of fungal infection after no engraft-
ment. Acute GVHD only occurred in those undergoing immune
modulation (2/10, grade 3). Of 8 evaluable, 2 developed exten-
sive cGVHD; 1 limited. There were no episodes of veno-
occlusive disease or mucositis; none required parenteral nutri-
tion. Patients were admitted to the hospital for 2 days during the
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